key: cord-0869760-12ci6iwh
authors: Morales‐Demori, Raysa; Mallory, George B.; Chartan, Corey; Coleman, Ryan; Ruiz, Fadel; Villafranco, Natalie; Whalen, Elise; Varghese, Nidhy
title: Outcomes of COVID‐19 infection in pediatric pulmonary hypertension: A single‐center experience
date: 2021-09-10
journal: Pediatr Pulmonol
DOI: 10.1002/ppul.25650
sha: b9261e01bc7867f744202ae223d97160405ccd27
doc_id: 869760
cord_uid: 12ci6iwh

BACKGROUND: The global COVID‐19 pandemic was particularly concerning for the pediatric pulmonary hypertension (PH) population due to immature immune systems and developmental comorbidities. This study aims to describe a single‐center experience of pediatric PH patients diagnosed with COVID‐19 disease. METHODS: A retrospective cohort study of all pediatric patients followed by the PH Center at Texas Children's Hospital diagnosed with COVID‐19 infection from April 2020 to February 2021. RESULTS: We identified 23 patients with a median age of 58 months (interquartile range [IQR]: 25–75th, 21–132 months), 48% being Hispanics. Eight patients (35%) required hospitalization; median length of stay was 6 days (IQR: 25–75th, 5–8 days). Only three of these eight patients required increased respiratory support. Targeted PH therapy was escalated in four patients (two in dual and two in triple therapy). There was one mortality in a patient with failing Fontan physiology. Ninety‐one percent of patients have had post‐COVID outpatient follow‐up, median of 101 days (IQR: 25–75th, 50–159 days) from diagnosis. Of the five patients with 6 min walk test (6MWT) data, three (60%) children walked less distance, median of −12 m (IQR: 25–75th, −12 to +49 m) compared to pre‐COVID testing. Postinfection pulmonary function testing (PFT) was notable for decrease in predicted forced vital capacity (FVC; median −6%, range −11% to +6%) and forced expiratory volume in one second (FEV1; median −14%, range −12% to −18%) in 75% of the patients with PFT data. CONCLUSION: In our institution, COVID‐19 was found more frequently in Hispanics and associated with low mortality.

At the onset of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Coronavirus 2, COVID-19) global pandemic, there was concern that patients of all ages with comorbidities, cardiovascular and pulmonary, would be at high risk for adverse outcomes from COVID disease. 1 Pulmonary hypertension (PH) is a severe disease marked by progressive pulmonary vascular disease and like other cardiorespiratory diseases, patients with PH are at particularly increased risk for clinical deterioration associated with respiratory infections. Acute respiratory failure in PH poses unique challenges due to negative hemodynamic effects due to mechanical ventilation and acidotic conditions affecting the efficacy of targeted pulmonary vasodilator therapy. 1 Unfortunately, underlying chronic respiratory disease has been reported to increase COVID mortality by 6%. 1 Additionally, COVID-19 has been associated with acute respiratory distress syndrome, a serious complication that could cause right ventricular (RV) systolic dysfunction, which, in patients with PH and chronic RV dysfunction, could be detrimental. 1 A few months into the pandemic, clinical reports suggested that PH patients were not as vulnerable as initially feared. 2 In one such early report, Horn et al. 2 described the collective experience of 32 PH centers in the United States and it was notable for 13 adult PH patients who required hospitalization due to COVID-19, 6 (55%) required mechanical ventilation and 1 died (8%). Authors hypothesized that the dysfunctional pulmonary endothelium 3 and inhibition of the angiotensin-2 receptors by endothelin receptor antagonist therapy offer a synergistic "protection" for the PH patient from COVID-19 infection. 2 "Protection" provided by PH disease may derive from the altered responses of the pulmonary endothelium.

The long-term outcomes of COVID-19 disease remain unknown in the pediatric population. This is true in the pediatric PH population as well, compounded by a dearth of clinical information on short-term outcomes as well. We, therefore, aim to describe a single-center experience of pediatric PH patients diagnosed with COVID-19 disease and short-term outcomes. 

We identified 23 pediatric PH patients who were diagnosed with COVID-19 infection, with a median age of 58 months (IQR: 25-75th, 21-132 months). WSPH class Group 1 (n:17 or 74%), Group 2 (n:2 or 9%), Group 3 (n:12 or 52%), and Group 5 (n:1 or 4%). Race/ethnicity distribution were Hispanic (n:11 or 48%), Caucasian (n:5 or 22%), African American (n:4 or 17%), and Asian (n:3 or 13%). Main comorbidities were congenital heart disease (n:17 or 74%), premature birth (n:5 or 39%), and congenital diaphragmatic hernia (n:3 or 13%). Congenital heart disease consisted of atrioventricular septal defect (n:5), secundum atrial septal defect (n:4), single ventricular physiology (n:3), pulmonary vein stenosis (n:2), Shone's complex (n:1), Tetralogy of Fallot (n:1), pulmonary artery stenosis (n:1), and congenitally corrected transposition of the great arteries (n:1).

At baseline, 11 patients (47%) were on respiratory support: continuous nasal cannula (n:5 or 45%) with flow range of 1/8 to 2 L per min, MORALES-DEMORI ET AL. Table 1 ).

Eight of the 23 COVID-19 positive patients (35%) required hospitalization due to perceived clinical worsening or acute 

The Texas Children's Hospital Pulmonary Hypertension Center actively manages a total of 299 patients, ranging from 4 months of age to 21 years old, and the majority are females (n:154 or 52%). The race/ethnicity distribution is Caucasians (n:107 or 36%), Hispanics (n:106 or 35%) and African Americans (n:64 or 21%). One-hundred thirty-seven patients (46%) have had tracheostomies. PH targeted therapies consist of none (n:91 or 30%), single (n:117 or 40%), dual (n:42 or 14%), and triple agents (n:49 or 16%).

As vulnerable as the PH population was initially feared to be, 1 to date, these patients have been less affected than patients with other comorbidities. 2,5 Our program is a large pediatric center, of which 8%

have had diagnosed COVID-19 disease, 3% have required hospitalization, and 0.3% have died due to this illness. This study supports that COVID-19 disease does not typically or seriously affect pediatric patients with PH, and mortality due to this illness is rare. Consistent with what has been previously reported locally, 6 we found that there is an ethnicity disparity characterized by Hispanics getting COVID-19 disease.

PH patients have had a lower incidence than expected of COVID-19 with respect both to diagnosis and complications. 1 None of our patients required intubation, or extracorporeal mechanical oxygenator use. One potential explanation for the low infectious rate is that our patients are young and accustomed to being in home isolation due to their medical complexity, history of complications due to infectious diseases, and/or need for technological support. 2, 7 Additionally, it has been proposed that a unique modulation of inflammatory response, either primary and developmental or secondary to the use of endothelin receptor antagonists and phosphodiesterase 5 inhibitors, have played a significant role in decreasing the severity of illness to COVID-19. 2, 3, 5 Our study found a slight female predominance (56%) in patients who got COVID-19 disease, as previously reported, 8 and consistent with the sex distribution in our PH population and with the national data from the Centers for Disease Control and Prevention. 9 Despite

Caucasians being the predominant race in our institution and consistent with our local data, 6 Hispanics represented the primary race/ ethnicity in our PH patients diagnosed and hospitalized with COVID-19. This finding is most likely due to our local demographics;

however, SARS-CoV-2 has been reported more frequently in racial minorities, 8, 10 Hispanics being the race/ethnic group most affected by this disease nationally. 9 Leeb et al. reported that Hispanics and African Americans required more hospitalizations and intensive care unit admissions. 10 The race/ethnicity disparity has been previously explained due to socioeconomic factors such as exposure from adult family members whose occupations require being front-line providers with difficulties in social distancing 10 Concerns have been expressed about the consequences of elevated PVR due to COVID-19 disease in the RV systolic function. 1 We have found that all, but two, of our patients with biventricular anatomy/physiology who underwent post-COVID echocardiogram as an outpatient had unchanged RV systolic function, although two had worsening TR severity, with one having worsening TR velocity compared to pre-COVID study. However, cardiac catheterization has not been performed in any of the 21 COVID-19 diagnosed patients to measure PVR postinfection.

In our institution, COVID-19 infection in pediatric PH patients was overall rare and well-tolerated. Very few required hospitalizations and of these, none required intubation or extracorporeal membrane oxygenation. While no risk factors were identified for COVID-19 diagnosis, infection was seen more frequently in Hispanics. Trisomy 21 patients with PH had a similar clinical course to non-Trisomy 21 PH children. Short-term follow-up has shown a negative impact on PFT and 6MWD; however, these functional tests will need to be followed long-term to determine the trajectory.

Although most of our pediatric PH patients have had favorable short-term outcomes of COVID-19 infection, the long-term consequences of this disease remain unknown and will need careful attention as a potential modifier of disease for the PH clinical landscape.

Care of patients with pulmonary arterial hypertension during the coronavirus (COVID-19) pandemic

Could pulmonary arterial hypertension patients be at a lower risk from severe COVID-19?

The role of endothelin-1 and endothelin receptor antagonists in inflammatory response and sepsis

Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management

COVID-19 and pulmonary hypertension in children: what do we know so far?

COVID-19 Kills Latinos at Disproportionate Rates -and the Numbers in Texas are Growing

SARS-CoV-2 infection in patients with down syndrome, congenital heart disease, and pulmonary hypertension: is down syndrome a risk factor?

COVID-19 trends among school-aged children -United States

Demographic Trends of COVID-19 Cases and Deaths in the US Reported to CDC

Hospitalization rates and characteristics of children aged <18 years hospitalized with laboratory-confirmed COVID-19 -COVID-NET, 14 States

SARS-CoV-2 community transmission disproportionately affects Latinx population during Shelter-in-Place in San Francisco

Prevalence of obesity among adults and youth: United States

Individuals with Down syndrome hospitalized with COVID-19 have more severe disease

Pulmonary function and COVID-19

How to cite this article

Outcomes of COVID-19 infection in pediatric pulmonary hypertension: a single-center experience

The authors declare that there are no conflict of interests.